We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ARQT market cap is 886.81M. The company's latest EPS is USD -2.7077 and P/E is -3.38.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.96M | 2.78M | 5.19M | 38.11M | 13.53M |
| Operating Income | -68.42M | -76.27M | -66.76M | -36.9M | -61.17M |
| Net Income | -72.02M | -80.1M | -70.99M | -44.77M | -66.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 3.69M | 59.61M |
| Operating Income | -43.13M | -136.65M | -206.53M | -301.63M | -241.1M |
| Net Income | -42M | -135.68M | -206.36M | -311.46M | -262.14M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 449.27M | 379.46M | 320.69M | 292.96M | 341.37M |
| Total Liabilities | 239.69M | 239.73M | 240.18M | 246.24M | 252.7M |
| Total Equity | 209.58M | 139.73M | 80.51M | 46.72M | 88.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 107.01M | 298.27M | 408.15M | 449.27M | 341.37M |
| Total Liabilities | 5.55M | 27.65M | 110.48M | 239.69M | 252.7M |
| Total Equity | -65.03M | 270.62M | 297.68M | 209.58M | 88.67M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -257.72M | -80.34M | -146.83M | -190.81M | -247.06M |
| Investing | -87.2M | 107.75M | 196.87M | 242.42M | 180.23M |
| Financing | 301.8M | 100k | 1.17M | 2.03M | 101.32M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -42.84M | -113.03M | -174.63M | -257.72M | -247.06M |
| Investing | -26.33M | -181.82M | -75.95M | -87.2M | 180.23M |
| Financing | 93.1M | 298.15M | 281.95M | 301.8M | 101.32M |
| Market Cap | 886.81M |
| Price to Earnings Ratio | -3.38 |
| Price to Sales Ratio | 14.88 |
| Price to Cash Ratio | 10.03 |
| Price to Book Ratio | 10 |
| Dividend Yield | - |
| Shares Outstanding | 96.81M |
| Average Volume (1 week) | 2.97M |
| Average Volume (1 Month) | 3.3M |
| 52 Week Change | -2.45% |
| 52 Week High | 13.17 |
| 52 Week Low | 1.76 |
| Spread (Intraday) | 11.2 (85.5%) |
| Company Name | Arcutis Biotherapeutics Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.arcutis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
